Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021

Covaxin shelf-life extended to 12 months from the date of manufacture

This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO

Built-for-purpose offering for biomolecule attribute monitoring

The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021

Laurus Labs PAT at Rs 201.90 cr. in Q2FY21

Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021

Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22

Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021

Transforming Healthcare Through AI

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.

Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore

Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21